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The influence of perioperative blood transfusion in oral and oropharyngeal squamous cell carcinoma remains uncertain. It is believed
that blood transfusion downregulates the immune system and may have an influence on cancer recurrence and survival. In all, 559
consecutive patients undergoing primary surgery for oral and oropharyngeal squamous cell carcinoma between 1992 and 2002 were
included in this study. Known prognostic variables along with transfusion details were obtained from head and neck cancer and blood
transfusion service databases, respectively. Adjusting for relevant prognostic factors in Cox regression, the hazard ratio for patients
having 3 or more transfused units relative to those not transfused was 1.52 (95% confidence interval (CI) 0.93–2.47) for disease-
specific and 1.52 (95% CI 1.05–2.22) for overall mortality. Blood transfusion of 3 or more units might confer a worse prognosis in
patients undergoing primary surgery for oral and oropharyngeal squamous cell carcinoma. Therefore, every effort should be made to
limit the amount of blood transfused to the minimum requirement.
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Perioperative blood transfusions are reported to be related to
cancer recurrence and reduced survival (Werther et al, 2001).
Different underlying mechanisms have been proposed, and
allogenic leucocytes in transfused blood have been suggested to
contribute to this phenomenon (Jensen et al, 1992). The
persistence of antigens in the recipient’s circulation might also
create an environment, which allows immune system down-
regulation. This possibility was supported by the evidence that
allogenic blood transfusion enhances renal allograft survival;
however, it has been hypothesised that blood transfusion-
associated immune depression might be deleterious in cancer
patients (Opelz et al, 1973; Gantt, 1981; Vamvakas and Blajchman,
2001). Although numerous clinical studies have addressed the
question of perioperative blood transfusion and cancer recurrence
and/or survival, the possibly harmful effect of allogenic blood
transfusion on immunomodulation remains unresolved.
To date, there is relatively little published data on blood
transfusion and outcome in oropharyngeal cancer (von Doersten
et al, 1992; Sturgis et al, 1997; Taniguchi and Okura, 2003). In head
and neck cancer, the effect of allogenic blood transfusion has been
reported on relatively small numbers of patients with conflicting
results (Table 1) (von Doersten et al, 1992; Woolley et al, 1992;
Sturgis et al, 1997; Vamvakas and Blajchman, 2001; Taniguchi and
Okura, 2003). Some authors have reported deleterious effects of
blood transfusion (Jones and Weissler, 1990; Woolley et al, 1992;
Taniguchi and Okura, 2003), while others could not confirm
transfusion as an independent predictive factor in multivariate
analysis (von Doersten et al, 1992; Schuller et al, 1994). A recent
paper by Taniguchi and Okura (2003), specific to oral and
oropharyngeal cancer, only showed the outcomes were worse with
3 or more units. This accumulating threshold effect of allogenic
blood transfusion has already been seen with colonic and
oesophageal cancers (Tartter, 1992; Langley et al, 2002). Hence,
we undertook this study to test the hypothesis that perioperative
blood transfusion has an adverse effect on survival of patients with
oral and oropharyngeal cancer.
MATERIALS AND METHODS
The study sample consisted of all consecutive patients undergoing
primary surgery for previously untreated oral and oropharyngeal
squamous cell carcinoma presenting to the Regional Maxillofacial
Unit Liverpool, between the years 1992 and 2002. The Liverpool
Oncology Head and Neck database was used to gather the clinical,
demographic, surgical, pathological and outcome data. The data
were downloaded into SPSS for further analyses.
Blood transfusion data were obtained from the centralised
transfusion database of the Haematology Department of University
Hospital Aintree. Perioperative haemoglobin levels were also
collected if available from the computerised laboratory reporting
system of the Haematology Department of University Hospital
Aintree.
The Office of National Statistics supplied details of
death certification for this patient cohort. Four clinicians
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sindependently attributed cause of death to oral cancer or other
causes. In 10 cases (4% of deaths), there was a 50:50 judgement
and further discussion between clinicians was required to reach a
verdict.
Statistical method
Association of factors with transfusion were tested by the w
2 test.
Kaplan–Meier methods were used to estimate oral cancer disease-
specific survival by patient groups and the log-rank test was used
to compare survival curves. Cox regression methods were used to
estimate the association of transfusion, and of transfusion with 3
or more units of blood, on survival after adjusting for covariates.
The 95% confidence intervals for unadjusted and adjusted hazard
ratios were obtained. Survival curve results were stratified by
tumour p stage and adjusted Cox regression hazard ratios
obtained. Stepwise Cox regression was used to find the best-fitting
survival model from all available covariates and the linear
prediction from this model was used to place patients into
similarly sized ‘lower’ and higher’ mortality risk groups. Survival
curves by transfusion status were compared within these risk
groups, and hazard ratios adjusted for the prognostic factors were
also computed. The cutoff at 3 units of transfused blood was
chosen to match the paper of Taniguchi and Okura (2003).
The preoperative haemoglobin cutoff value of 10gdl
 1 was set
according to existing transfusion guidelines. Preoperation haemo-
globin levels were routinely recorded from 1997 and were not
included in the main prognostic analyses from 1992, but were
included in separate analyses of the data from 1999 to 2002,
analyses specifically undertaken to assess the situation following
the adoption of leuco-depletion of blood in Aintree Hospitals from
January 1999.
RESULTS
The cohort comprised 559 patients undergoing primary surgery
from 1992 to 2002 for previously untreated oral and oropharyngeal
squamous cell carcinoma. Almost all (96%, 1342 of 1397)
transfused units of blood during this time were for 437 patients
having free-flap surgery. During the operation, 77% (337 of 437)
were transfused with blood and 68% (223 of 330) of these received
3 or more units of blood, units unknown for seven patients.
Transfusion rates per se, and rates for transfusions with 3 or more
units, were highest for free-flap surgery patients with more
advanced stages of disease, when soft-tissue margins were
involved, with perineural invasion, for segmental resection and
for composite-flap surgery (Table 2).
The 5-year Kaplan–Meier estimate of oral cancer survival for
patients receiving blood was 67% (s.e. 3%) as compared with 78%
(s.e. 3%) for those not transfused. The relative risk of death
(hazard ratio) from patients having a blood transfusion alone was
estimated from Cox regression to be 1.59 (95% confidence interval
(CI) 1.00–2.54). There was little difference in survival between
those having no transfusions and those having 1 or 2 units
transfused, but there was worse survival in those having 3 or more
units transfused (Figure 1). The hazard ratio for patients with 3 or
more transfused units was 1.93 (95% CI 1.20–3.11) relative to
those not transfused.
Many clinical and pathological factors were associated with
disease-specific survival (Table 3) and there was inter-correlation
between pathological factors. Patients having 3 or more units had
the worse survival for both p1–2 and p3–4 stage tumours
(Figure 2), and adjusting for p stage in Cox regression gave hazard
ratios of 1.35 (95% CI 0.84–2.16) for transfusion and 1.56 (95% CI
0.96–2.52) for transfusion with 3 or more units. When all factors
(of Table 3) were entered into a stepwise Cox regression (Po0.01
for entry), the two predictors selected were pN status and margins.
The linear prediction from the regression model was used to place
patients into similarly sized lower and higher risk groups. In effect,
the lower risk group comprised 221 patients either with clear
margins and pN0/pN1 or with close margins and pN0. Within each
risk group, patients with 3 or more transfused units had the worst
survival (Figure 3). Adjusting for pN status and margins in Cox
regression gave a hazard ratio of 1.29 (95% CI 0.80–2.08) for
transfusion and 1.52 (95% CI 0.93–2.47) for transfusion with 3 or
more units.
All-cause mortality rates for patients receiving blood was 48%
(s.e. 3%) as compared with 65% (s.e. 5%) for those not transfused.
We found the same univariate predictors of all-cause mortality as
for disease specific (data not shown). Cox regression gave
unadjusted hazard ratios of 1.61 for transfusion and 1.84 for
Table 1 Effect of allogenic blood transfusion in other studies involving head and neck cancer patients
Author (year) Disease
No. in
study
Transfusion
rate (%) Outcome Results
Taniguchi and Okura (2003) Oral/oropharyngeal 105 32 5-year crude survival Po0.01 (43 units)
Moir et al (1999) Larynx 165 36 Recurrence Po0.04 (autologous vs
heterologous)
Leon et al (1996) Oral/oropharyngeal 269 32 Recurrence No effect
Larynx/hypopharynx
Barra et al (1994) Larynx/oral/
oropharyngeal
207 73 5-year crude survival Po0.05
Schuller et al (1994) Larynx/oral/
oropharyngeal
217 61 5-year crude survival No effect
von Doersten et al (1992) Larynx/paranasal/oral 104 49 Recurrence, infection No effect
Oropharyngeal
Woolley et al (1992) Larynx/hypopharynx 143 69 Recurrence Po0.009
Alun-Jones et al (1991) Larynx 69 55 5-year survival Po0.05
Bock et al (1990) Larynx/hypopharnyx 174 81 Recurrence, infection No effect
5-year crude survival
Jones and Weissler (1990) Larynx/oral/
oropharyngeal
90 51 Recurrence Po0.05
All studies reporting a significant difference do so for worse outcome associated with allogenic blood transfusion.
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sTable 2 Association of factors with blood transfusion for patients having free-flap surgery
Not transfused Transfused o3 units Transfused 3+ units
Patients % n % n % nP -value*
Gender
Male 274 22 60 29 79 49 135 0.28
Female 156 21 33 22 35 56 88
Age (years)
o55 133 27 36 24 32 49 65 0.60
55–64 123 20 25 30 37 50 61
65–74 115 18 21 26 30 56 64
75+ 59 19 11 25 15 56 33
Tumour site
Buccal 76 21 16 24 18 55 42 0.11
Lower gum 47 13 6 32 15 55 26
Tongue (ant. 2/3) 87 28 24 32 28 40 35
Floor of mouth 129 26 33 26 33 49 63
Other 91 15 14 22 20 63 57
Type of flap
Soft 309 24 74 29 91 47 144 0.003
Composite 119 15 18 19 22 66 79
ASA
I 105 29 30 28 29 44 46 0.23
II 208 20 42 25 53 54 113
III (n¼77), IV(n¼2) 79 16 13 27 21 57 45
Unknown 38 21 8 29 11 50 19
Adjuvant radiotherapy
No 214 26 55 27 57 48 102 0.10
Yes 216 18 38 26 57 56 121
Mandibular resection
Nil 230 26 60 28 64 46 106 o0.001
Rim 73 22 16 37 27 41 30
Segment 127 13 17 18 23 69 87
ECS
No ECS 313 22 69 27 83 51 161 0.94
ECS 117 21 24 27 31 53 62
Positive nodes
No 230 24 56 27 61 49 113 0.30
Yes 200 19 37 27 53 55 110
Margins
Clear 45mm 187 27 50 27 51 46 86 0.001
Close o5mm 147 25 37 24 35 51 75
Involved 93 5 5 30 28 65 60
pT stage
Tis, 1–2 218 31 68 31 68 38 82 o0.001
3–4 210 12 25 21 45 67 140
pN
0, no neck 223 24 53 26 59 50 111 0.83
17 8 2 1 1 6 2 6 2 0 5 4 4 2
2–3 129 19 24 27 35 54 70
P stage
1–2 121 34 41 27 33 39 47 o0.001
3–4 307 17 52 26 80 57 175
Tumour differentiation
Poor 55 11 6 20 11 69 38 0.04
Moderate 274 23 63 29 80 48 131
Well 99 23 23 22 22 55 54
Pattern of invasion
Favourable 104 21 22 31 32 48 50 0.46
Unfavourable 323 22 70 25 80 54 173
Perineural invasion
No 304 25 77 27 81 48 146 0.009
Yes 126 13 16 26 33 61 77
Vascular invasion
No 289 24 69 26 75 50 145 0.27
Yes 141 17 24 27 39 55 78
ASA¼American Society of Anesthesiologists; ECS¼extracapsular spread. *w
2 test. Note the table excludes seven patients who had transfusions, but the number of units was
unknown. T and N stage: Tis is in situ, 1 is 2cm or less, 2 is more than 2cm upto 4cm, 3 is more than 4cm up to 6cm, 4 is greater than 6cm or involving adjacent structures.
Nodal stage: N0: No evidence of regional lymph node metastasis. N1: Metastasis in a single ipsilateral (same side) lymph node, 3cm or less in size. N2: Metastasis in a single
ipsilateral (same side) lymph node more than 3cm but not more than 6cm in greatest dimension, or metastasis in multiple ipsilateral (same side) lymph nodes, none more than
6cm in greatest dimension, or metastasis in bilateral (both) or contralateral (opposite side) lymph nodes, none more than 6cm in greatest dimension. N3: Metastasis in a lymph
node more than 6cm in greatest dimension. P stage is a combination of T and N status.
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stransfusion of 3 or more units, and adjustment for pN status,
margins, age and perineural invasion (independent predictors at
Po0.01) gave hazard ratios of 1.35 (95% CI 0.94–1.93) for
transfusion and 1.52 (95% CI 1.05–2.22) for transfusion with 3 or
more units.
Preoperation haemoglobin levels were routinely recorded from
1997 and were known for 81% (190 of 234). Transfusion rates were
81% (43 of 53) for patients with haemoglobin levels of 10 and
under and 70% (95 of 136) for levels over 10. Rates for transfusion
with 3 or more units were 47% (25 of 53) and 39% (53 of 136),
respectively. The 5-year disease-specific survival rates were 65%
(s.e. 7) and 78 (s.e. 4), P¼0.19, and for all-cause survival, 44% (s.e.
7) and 60% (s.e. 5), P¼0.07. The mean (s.d.) haemoglobin level
was 12.2 (2.3) for patients not transfused, 11.9 (2.6) for those
transfused 1–2 units and 11.3 (2.3) for those transfused 3 or more
units. For patients transfused with 3 or more units, the observed
disease-specific survival was worse for those with preoperative
haemoglobin levels of p10 (Figure 4), unadjusted hazards ratio
1.71 (95% CI 0.79–3.68) and after adjustment for pN status and
margins 1.92 (95% CI 0.87–4.27).
From the beginning of January 1999, leuco-depletion of blood
was introduced at University Hospital Aintree. In separate analyses
of the data from 1999 for disease-specific survival, Cox regression
methods gave unadjusted hazard ratios of 1.72 for transfusion
and 2.22 for transfusion of 3 or more units, and after adjustment
(pN status and margins), 1.34 (95% CI 0.63–2.85) for transfusion
and 2.09 (95% CI 0.94–4.78) for 3 or more units. For all-cause
survival, adjusted (pN status, margins, age and perineural
invasion) ratios were 1.48 (95% CI 0.81–2.68) and 1.60 (95% CI
0.82–3.11).
Transfusion rates have fallen over time, 86% (239 of 279) before
1999 and 65% (98 of 151) from 1999 to 2002. Rates for transfusion
with 3 or more units were 59% (165 of 279) and 38% (58 of 151),
respectively. Before 1999, 5-year disease-specific survival was 68%
(s.e. 3) and overall survival 51% (3), whereas from 1999 to 2002, 5-
year disease-specific survival was 72% (s.e. 4) and overall survival
48% (5).
In the whole cohort, there was a higher rate of recurrence for
patients transfused with 3 or more units (29%, 65 of 223) than for
patients transfused with 1–2 units (19%, 22 of 114) and for
patients not transfused (19%, 18 of 93) P¼0.06 w
2 test. Local-only
recurrence rates were 14% (31 of 222), 8% (nine of 114) and 6%
(six of 93), respectively, P¼0.08.
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Figure 1 Kaplan–Meier disease-specific survival by whether patients had
no blood transfusion, were transfused with 1–2 units or transfused with 3
or more units of blood.
Table 3 Association of factors with disease-specific survival for patients
having free-flap surgery
Disease specific
Patients 2 years 5 years P-value*
Blood transfusion
No 93 81 79 0.001
o3 units 114 84 79
3+ units 223 67 61
Gender
Male 279 76 71 0.29
Female 158 72 65
Age (years)
o55 137 80 76 0.008
55–64 125 73 66
65–74 115 77 75
75+ 60 58 50
Tumour site
Buccal 76 74 69 0.51
Lower gum 47 79 74
Tongue (ant. 2/3) 91 71 67
Floor of mouth 132 78 73
Other 91 72 64
ASA
I 109 81 79 0.07
II 210 74 66
III/IV 80 71 64
Unknown 38 68 62
Type of flap
Soft 316 76 71 0.29
Composite 119 71 66
Adjuvant radiotherapy
No 220 81 77 0.002
Yes 217 69 62
Mandibular resection
Nil 237 77 73 0.11
Rim 73 79 70
Segment 127 68 63
ECS
No ECS 320 83 77 o0.001
ECS 117 52 46
Positive nodes
No 237 86 81 o0.001
Yes 200 61 55
Margins
Clear 45mm 192 89 84 o0.001
Close o5mm 149 71 64
Involved 93 50 46
pT stage
Tis, 1–2 224 82 77 o0.001
3–4 211 66 61
pN
0, no neck 230 87 82 o0.001
17 8 7 3 6 8
2–3 129 53 47
P stage
1–2 127 90 86 o0.001
3–4 308 68 62
Tumour differentiation
Poor 55 58 52 o0.001
Moderate 279 72 66
Well 100 89 87
Pattern of invasion
Favourable 105 91 88 o0.001
Unfavourable 329 69 63
Perineural invasion
No 307 80 74 o0.001
Yes 130 60 56
Vascular invasion
No 294 82 76 o0.001
Yes 143 60 54
ASA¼American Society of Anesthesiologists; ECS¼extracapsular spread. *Log-rank
test. Table gives 2- and 5-year Kaplan–Meier survival rates.
The influence of allogenic blood transfusion
T Szakmany et al
650
British Journal of Cancer (2006) 94(5), 647–653 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDISCUSSION
In this large cohort of patients with oral and oropharyngeal cancer,
the biggest influences on disease-specific and all-cause mortality
were related to tumour pathology, resection margins and nodal
status. Death certification was used to help give an indication as to
the cause of death and help determine disease-specific survival.
Although death certification in the absence of post mortem has its
limitations owing to reporting errors, it has been shown to be of
value in this cancer group (Leitner et al, 2001). Mortality was
observed to be higher among patients receiving allogenic blood
transfusion and higher still for those receiving 3 or more units.
This association persisted after adjusting for confounding factors.
These results were in keeping with those from previous authors,
but were at the borderline of statistical significance (von Doersten
et al, 1992; Woolley et al, 1992; Vamvakas and Blajchman, 2001;
Taniguchi and Okura, 2003).
In the management of oral and oropharyngeal cancer prolonged
surgical procedures involving tumour resection and reconstruction
using free tissue transfer techniques will frequently result in
significant intraoperative blood loss. Reported transfusion rates
have varied widely from 32 to 81%, with more recent studies
reporting lower transfusion rates (Taniguchi and Okura, 2003).
This is in keeping with our experience, we observed a halving in
transfusion rate from 88% in 1992 to 44% in 2002. It might be that
more recent patients who have transfusion are more anaemic than
patients earlier in the series. Hence, preoperative anaemia
associated with transfusion may explain the enhanced hazard
ratios from 1999 onwards. However, we cannot properly analyse
the whole cohort, with respect to properative anaemia, owing to
the lack of haemoglobin data prior to 1997. Survival is affected by
several factors including malignancy stage, tumour resection
margins and chronic systemic illness, all of which are confounding
factors for allogenic blood transfusion (de Cassia Braga Ribeiro
et al, 2003). A recent meta-analysis, which summarised findings of
several observational studies, failed to show any significant
outcome benefit between transfused and nontransfused patients
(Vamvakas and Blajchman, 2001). Transfusion itself was asso-
ciated with a 2.5-fold increase in mortality before adjustment for
other factors, similar to our results presented above. In contrast to
Vamvakas, however, our data suggest that transfusion of 3 or more
units of blood is associated with a worse outcome in oropharyngeal
cancer patients, with a reduction in survival and an increase in
recurrence rates. Our data reinforce those of Taniguchi who
observed an almost five-fold increase in the risk of death among
patients transfused more than 3 units of blood compared to
nontransfused patients (Taniguchi and Okura, 2003). Our data
suggest that transfusion of 3 or more units of blood could confer a
worse 5-year survival in oral cancer patients. Our patients were
stratified into high- and low-risk groups, with this effect being
observed in both groups (Figures 2 and 3). It seems, although more
advanced disease carries a significantly worse prognosis, blood
transfusion itself may accentuate this deleterious effect. To clearly
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Figure 2 Kaplan–Meier disease-specific survival by blood transfusion
and p stage.
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Figure 3 Kaplan–Meier disease-specific survival by blood transfusion
and risk group (derived from Cox regression based on pN status and
margins).
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sanswer the question whether blood transfusion affects survival, a
randomised controlled trial is required. This would need to be
multicentre and would involve withholding blood or blood
products.
To date, clinical trials are inconclusive as to whether tumour
recurrence rate is higher after transfusion in head and neck cancer
(Jones and Weissler, 1990; Sturgis et al, 1997). Our study suggests
that the local and systemic cancer recurrence rate is higher in those
patients who were transfused with 3 or more units of blood. Given
that the volume of blood transfused appears to be of prime
importance in this worsened outcome, it is likely that the
underlying cause is a dose-related immune suppression. The
earliest reports of immunomodulation after blood transfusion in
the 1970s were in the field of renal transplantation where
transfusion before transplantation was accompanied with an
improved allograft survival (Opelz et al, 1973; Opelz and Terasaki,
1978). Improved graft survival is associated with an increasing
number of transfusions before transplantation, with a near
maximal benefit after 5 units (Opelz and Terasaki, 1978). These
data suggest that there may be an immunomodulatory threshold
effect related to volume of blood transfused. In the context of
cancer surgery, a similar finding has been demonstrated in that the
adverse influence of blood transfusion on survival is seen only
after larger transfusions for colorectal tumours, soft-tissue
sarcomas and oesophageal cancers (Rosenberg et al, 1985; Tartter,
1992; Langley et al, 2002). Our results would appear to support the
existence of a threshold effect, which has been demonstrated
previously (Langley et al, 2002; Taniguchi and Okura, 2003).
Transfusion-related immunosuppression consists of a mono-
cyte-mediated early phase and a later phase, which is characterised
by increased suppressor T-cell activity. Both effects appear to be
dependent on the number of transfusions (Dellinger and Anaya,
2004). Allogenic blood transfusion has been shown to impair
natural killer cell function and also inhibit interleukin-2 produc-
tion, both mechanisms crucial for normal antitumour activity
(Dellinger and Anaya, 2004).
Although it is not entirely clear at molecular level which factors
modulate the effects of allogenic blood transfusion in cancer
surgery, there is good evidence that leucocytes in the blood
mediate them (Jensen et al, 1992).
The patients in the current study did not have leukocyte-
depleted transfusions until 1999, since when all allogenic blood for
transfusion in our hospital has been leucocyte depleted. This is
part of a nationwide policy in the United Kingdom aimed at
minimising the possibility of variant Creutzfeldt–Jakob disease
being passed through transfusion of blood orblood products.
Although most of the possible detrimental effects of blood
transfusion are thought to be mediated via the transfused
leucocytes, we were unable to find any significant differences in
the clinical outcome of patients before and after the leucocyte
depletion policy was implemented.
It has been postulated that preoperative haemoglobin levels are
independent predictors of survival in head and neck cancer
(Macdonald and Hurman, 2004). In our series, we observed that
patients who received 3 or more units of blood and had low
preoperative haemoglobin had worse survival compared to those
who had normal haemoglobin levels (Figure 4). This effect was less
marked among those patients who received only 1–2 units of
blood (Figure 4). This may suggest that patients whose disease is
more advanced and manifests in severe preoperative anaemia
mainly owing to reduced oral intake and dietary problems are
much more vulnerable to the deleterious immunosuppressive
effects of a larger allogenic blood transfusion.
Despite the limitations of the current study, including its
retrospective nature, the results support previous work that
demonstrated an adverse effect on survival of patients undergoing
resection for oral carcinoma who receive an allogenic blood
transfusion (Woolley et al, 1992; Taniguchi and Okura, 2003).
Clinical trials with erythropoietin and acute normovolaemic
haemodilution have shown promising results in the reduction of
allogenic blood product requirements in maxillofacial surgery;
however, the importance of the meticulous surgical technique
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Figure 4 Kaplan–Meier disease-specific survival by blood transfusion
and preoperation haemoglobin level.
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scannot be overemphasised (Scott et al, 2002; Habler et al,
2004). Clinicians must be cognizant of the 3 unit threshold and
should attempt to limit transfusion volume whenever it is safe to
do so.
In conclusion, this study reaffirms the importance of complete-
ness of resection and the importance of lymph node involvement
in resection for oral carcinoma. In addition, it suggests that
transfusion of 3 or more units of blood could adversely affect
survival. Therefore, every effort should be made to limit the
amount of blood transfused to the minimum requirement.
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